Community and patient values for preventing herpes zoster

  • Lieu T
  • Ortega-Sanchez I
  • Ray G
 et al. 
  • 20


    Mendeley users who have this article in their library.
  • 26


    Citations of this article.


The US Advisory Committee on Immunization Practices has recently recommended a new vaccine against herpes zoster (shingles) for routine use in adults aged > or =60 years. However, estimates of the cost effectiveness of this vaccine vary widely, in part because of gaps in the data on the value of preventing herpes zoster. Our aims were to (i) generate comprehensive information on the value of preventing a range of outcomes of herpes zoster; (ii) compare these values among community members and patients with shingles and post-herpetic neuralgia (PHN); and (iii) identify clinical and demographic characteristics that explain the variation in these values.

Author-supplied keywords

  • Contingent valuation
  • Herpes zoster, assessment
  • Postherpetic neuralgia, assessment
  • Utility measurement
  • Varicella zoster virus vaccine live, therapeutic use
  • Willingness to pay

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Tracy A. Lieu

  • Ismael Ortega-Sanchez

  • G. Thomas Ray

  • Donna Rusinak

  • W. Katherine Yih

  • Peter W. Choo

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free